← Back to Treatments
🏅 FDA Orphan Designation

Vyndaqel

TAFAMIDIS MEGLUMINE

Manufacturer: Pfizer Laboratories Div Pfizer Inc

Indicated for:
Wild type ATTR amyloidosisOrphanHereditary ATTR amyloidosisOrphanHereditary transthyretin-mediated amyloidosis

FDA-Approved Indications (3)

Wild type ATTR amyloidosisOrphan Designation
Hereditary ATTR amyloidosisOrphan Designation

indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospit…

Population: adults

Indications & Usage

1. INDICATIONS AND USAGE VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. ( 1 )

💙 Support Programs

View all →
Vyndaqel
Pfizer Laboratories Div Pfizer Inc
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.